Author’s response to reviews

Title: Association of white matter hyperintensities with migraine features and prognosis

Authors:
Hui Xie (282193319@qq.com)
Qiang Zhang (zqxjtu2008@163.com)
Kang Huo (huokangster@qq.com)
Rui Liu (youyoubingguo128@126.com)
Zhi-Jie Jian (jianzhijie80@126.com)
Yi-Tong Bian (bianyt0323@163.com)
Guo-Liang Li (liguoliang_med@163.com)
Dan Zhu (767441726@qq.com)
Li-Hui Zhang (1062935708@qq.com)
Jian Yang (cjr.yangjian@vip.163.com)
Guo-Gang Luo (lguogang@163.com)

Version: 3 Date: 26 May 2018

Author’s response to reviews:

BMC Neurology
May 26th, 2018

Dear Dr. Minien

Thanks for your decision on our manuscript (NURL-D-17-00434R2) entitled “Association of WMHs with migraine features and prognosis”. We also would like to thank you for the useful comments. A point-by-point response letter is attached below.
This revised manuscript has been edited and proofread by Medjaden Bioscience Limited. We hope that the revised version is now acceptable for publication

Sincerely,

Guo-Gang Luo
Department of Neurology,
The First Affiliated Hospital of Xi’an Jiaotong University,
No. 277 Yanta West Road, Xi’an 710061, Shaanxi, China.
Tel.: 86-13991974085;
E-mail: lguogang@163.com

Reply to editor
1. Title:
   Please avoid using abbreviations (e.g. WMHs) in the title.
   Response: Thanks for your comment. We modified the title accordingly.

2. Consent to Participate:
   In the declarations, please confirm whether written or verbal informed consent was obtained from all participants. If verbal, please state the reason and whether the ethics committee approved this procedure. If the need for consent was waived by an IRB or is deemed unnecessary according to national regulations, please clearly state this, including the name of the IRB or a reference to the relevant legislation.

   Response: Thanks for your comment. A written informed consent was obtained from all participants included in this study. We have addressed this detail in the declarations (page 18, line 413).

3. Consent for Publication:
   Please amend the statement in the "Consent for publication" section, as this refers to consent obtained to publish potentially-identifying information (of patients/participants). Seeing as this is not applicable to your manuscript please state “Not Applicable” in this section.

   Response: Thanks for your comment. We have amended this point (page 18, line 417).

4. Availability of Data and Materials:
   Thank you for providing an Availability of data and materials subheading in your Declarations section. Please describe where the raw data generated/analysed during your study can be found, if any is unaccounted for. If you wish to share the data through correspondence then please include the statement “The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.” If you do not wish to share your data, please state this along with the reason.
Response: Thanks for your comment. We wish to share the data through correspondence and we have stated that “The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request” (page 18, line 420).

5. Clean Manuscript:
At this stage, please upload your manuscript as a single, final, clean version that does not contain any tracked changes, comments, highlights, strikethroughs or text in different colours. All relevant tables/figures/additional files should also be clean versions. Figures (and additional files) should remain uploaded as separate files.
Response: Thanks for your comment. We edit the manuscript accordingly.